These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27896415)

  • 1. Predicting risk factors for varicella zoster virus infection and postherpetic neuralgia after hematopoietic cell transplantation using ordered logistic regression analysis.
    Kanbayashi Y; Matsumoto Y; Kuroda J; Kobayashi T; Horiike S; Hosokawa T; Taniwaki M
    Ann Hematol; 2017 Feb; 96(2):311-315. PubMed ID: 27896415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
    Onozawa M; Hashino S; Haseyama Y; Hirayama Y; Iizuka S; Ishida T; Kaneda M; Kobayashi H; Kobayashi R; Koda K; Kurosawa M; Masauji N; Matsunaga T; Mori A; Mukai M; Nishio M; Noto S; Ota S; Sakai H; Suzuki N; Takahashi T; Tanaka J; Torimoto Y; Yoshida M; Fukuhara T
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):724-9. PubMed ID: 19450757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
    Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
    Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varicella Zoster Virus Infection in Children with Autologous Hematopoietic Cell Transplantation: A Retrospective, Single-Center Study in Korea.
    Kang JM; Kim JM; Lee JW; Yoo KH; Sung KW; Koo HH; Kim YJ
    Biol Blood Marrow Transplant; 2020 May; 26(5):965-971. PubMed ID: 31962166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies.
    Sahoo F; Hill JA; Xie H; Leisenring W; Yi J; Goyal S; Kimball LE; Lee I; Seo S; Davis C; Pergam SA; Flowers ME; Liaw KL; Holmberg L; Boeckh M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):505-511. PubMed ID: 28039754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
    Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.
    Han SB; Kim SK; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH
    Medicine (Baltimore); 2017 Apr; 96(14):e6546. PubMed ID: 28383421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of varicella zoster virus infection morbidity and mortality in pancreas and kidney-pancreas transplant recipients.
    Netchiporouk E; Tchervenkov J; Paraskevas S; Sasseville D; Billick R
    Transplant Proc; 2013 Mar; 45(2):701-4. PubMed ID: 23453544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
    Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
    Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation.
    Offidani M; Corvatta L; Olivieri A; Mele A; Brunori M; Montanari M; Rupoli S; Scalari P; Leoni P
    Clin Infect Dis; 2001 May; 32(10):1414-22. PubMed ID: 11317241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population.
    Rogers JE; Cumpston A; Newton M; Craig M
    Transpl Infect Dis; 2011 Oct; 13(5):480-4. PubMed ID: 21615848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic Cell Transplantation Recipients on Standard Acyclovir Prophylaxis.
    Baumrin E; Cheng MP; Kanjilal S; Ho VT; Issa NC; Baden LR
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1642-1647. PubMed ID: 31004745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for postherpetic neuralgia using ordered logistic regression analysis.
    Kanbayashi Y; Onishi K; Fukazawa K; Okamoto K; Ueno H; Takagi T; Hosokawa T
    Clin J Pain; 2012 Oct; 28(8):712-4. PubMed ID: 22209800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
    Wada-Shimosato Y; Tanoshima R; Hiratoko K; Takeuchi M; Tsujimoto SI; Shiba N; Ito S; Yamanaka T; Ito S
    Transpl Infect Dis; 2019 Jun; 21(3):e13061. PubMed ID: 30756465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VZV skin-test reaction, but not antibody, is an important predictive factor for postherpetic neuralgia.
    Imoto K; Okazaki A; Onishi F; Miyazaki Y; Okeda M; Yano S; Takao Y; Gomi Y; Ishikawa T; Okuno Y; Mori Y; Iso H; Yamanishi K; Asada H;
    J Dermatol Sci; 2015 Sep; 79(3):235-40. PubMed ID: 26070505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
    Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
    Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of S-LANSS, a tool for screening neuropathic pain, for predicting postherpetic neuralgia in patients after acute herpes zoster events: a single-center, 12-month, prospective cohort study.
    Cho SI; Lee CH; Park GH; Park CW; Kim HO
    J Pain; 2014 Feb; 15(2):149-56. PubMed ID: 24342706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Japanese single-hospital observational trial with a retrospective case-control analysis of varicella zoster virus reactivation after autologous peripheral blood stem cell transplantation.
    Mawatari M; Isoda A; Miyazawa Y; Sawamura M; Matsumoto M
    Transpl Infect Dis; 2015 Aug; 17(4):544-50. PubMed ID: 26041667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.